Alan Solinsky, MD
Ophthalmology · West Hartford, CTNPI 1235103904
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.8%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.7%. Among ophthalmology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 306 payments — averaging $42.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$2K
- AbbVie$2K
- Rxsight Inc$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- Bausch & Lomb Americas Inc.$1K
- Alcon$947
- plus $3K from 23 others
Across 6 payments — averaging $3666.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$22K
What the payments were for
- Consulting fees$3,08023%
- Speaking & faculty fees$1,52812%
- Grants$5004%
- Food & beverage$6,53550%
- Education$1,0008%
- Other$4684%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 12 | $2,451 |
| AbbVie(2 entities) | 55 | $1,883 |
| Rxsight Inc | 7 | $1,684 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $1,626 |
| Bausch & Lomb Americas Inc. | 33 | $1,024 |
| Alcon | 17 | $947 |
| Sun Pharmaceutical Industries Inc. | 27 | $536 |
| Harrow Eye, LLC | 44 | $491 |
| Novartis | 23 | $483 |
| Kala Pharmaceuticals, Inc. | 19 | $385 |
| Oyster Point Pharma, Inc. | 11 | $268 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $228 |
| Tarsus Pharmaceuticals, Inc. | 9 | $169 |
| Omeros Corporation | 2 | $144 |
| Astellas Pharma US Inc | 1 | $124 |
| Sight Sciences, Inc. | 3 | $104 |
| Ocular Therapeutix, Inc. | 6 | $94 |
| Amgen | 4 | $86 |
| Dompe US, Inc. | 3 | $63 |
| Apellis Pharmaceuticals, Inc. | 2 | $60 |
| Glaukos Corporation | 1 | $50 |
| Biotissue Holdings Inc. | 3 | $46 |
| Eyevance Pharmaceuticals LLC | 3 | $43 |
| Rayner Intraocular Lenses Limited | 2 | $33 |
| Coopervision Inc. | 2 | $25 |
| Thea Pharma Inc. | 1 | $21 |
| Carl Zeiss Meditec Cataract Technology Inc. | 1 | $20 |
| Eyepoint US, Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$2,351
- Rocklatan$2,351
- RXSIGHT CONTACT LENS$1,616
- RXSIGHT INJECTOR CARTRIDGE$1,616
- RXSIGHT INJECTOR HANDPIECE$1,616
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$1,616
- LIGHT ADJUSTABLE LENS (LAL)$1,616
- LOTEMAX$1,500
- PROLENSA$1,500
- BIOTRUE$1,500
- ULTRA$1,500
- RESTASIS$600
- COMBIGAN$500
- ALPHAGAN P$500
- Unity$468
- IC-8 Apthera IOL$251
- Tecnis Simplicity$127
- LUMIGAN$125
- OMIDRIA$125
- MIEBO$125
How this compares
$13,111 in reported general payments places this provider in the 90th percentile of 279 ophthalmology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 267 | $305,828 |
| LumiganBimatoprost | 179 | $120,175 |
| XiidraLifitegrast | 77 | $109,042 |
| MieboPerfluorohexyloctane/Pf | 108 | $89,293 |
| ProlensaBromfenac Sodium | 201 | $71,381 |
| RhopressaNetarsudil Mesylate | 129 | $69,683 |
| Prednisolone Acetate | 802 | $56,594 |
| RocklatanNetarsudil Mesylat/Latanoprost | 86 | $45,264 |
| CequaCyclosporine | 68 | $44,966 |
| CombiganBrimonidine Tartrate/Timolol | 82 | $41,568 |
| Cyclosporine | 89 | $37,777 |
| Bromfenac Sodium | 145 | $30,764 |
| TyrvayaVarenicline Tartrate | 31 | $28,226 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 186 | $25,484 |
| MoxifloxacinMoxifloxacin Hcl | 815 | $21,066 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,883 | $467,572528 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $1,024 | $215,447211 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $2,451 | $114,948215 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $1,626 | $84,237262 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $536 | $44,96668 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $268 | $28,22631 claims |
| AlconSimbrinza | $947 | $13,09447 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $385 | $5,53611 claims |
| Eyevance Pharmaceuticals LLCZerviate | $43 | $3,43811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 279 ophthalmology providers in Connecticut.
Other ophthalmology in West Hartford
- David JengWest Hartford$7K
- Christopher OrrWest Hartford$7K
- Lyndon LeeWest Hartford$7K
- Jeremy HwangWest Hartford$6K
- Neeru DuaWest Hartford$4K
- John HuangHartford$267K
- Amir CohenNew Haven$266K
- James MurphyHamden$176K
- James TalbotNew Canaan$47K
- Paul KangNew Haven$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.